Pfizer Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.83B | $52.55B | $52.82B | $48.85B | $49.61B | $51.58B | $54.66B | $61.04B |
| US | — | $24.82B | $26.12B | $23.43B | $19.72B | $20.38B | — | — |
| International | — | $27.73B | $26.70B | $25.42B | $29.89B | $31.20B | — | — |
| Cost of Revenue | $8.99B | $11.23B | $12.32B | $9.65B | $9.58B | $9.59B | $9.82B | $12.50B |
| Gross Profit | $31.84B | $41.32B | $40.50B | $39.20B | $40.03B | $42.00B | $44.84B | $48.54B |
| Gross Margin | 78.0% | 78.6% | 76.7% | 80.3% | 80.7% | 81.4% | 82.0% | 79.5% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $12.61B | $14.80B | $14.84B | $14.81B | $14.10B | $14.36B | $15.17B | $17.58B |
| Operating Income | $4.91B | $13.58B | $9.54B | $10.16B | $13.60B | $17.13B | $12.76B | $13.16B |
| Operating Margin | 12.0% | 25.8% | 18.1% | 20.8% | 27.4% | 33.2% | 23.4% | 21.6% |
| Interest Expense | $1.32B | $1.27B | $1.19B | $1.20B | $1.36B | $1.41B | $1.52B | $1.68B |
| Pretax Income | $3.59B | $12.31B | $8.35B | $8.97B | $12.24B | $15.72B | $11.24B | $11.48B |
| Income Tax Expense | $-266.0M | $-9.05B | $1.12B | $1.99B | $3.12B | $4.31B | $2.22B | $3.62B |
| Net Income | $11.15B | $21.31B | $7.22B | $6.96B | $9.14B | $22.00B | $14.57B | $10.01B |
| Net Margin | 27.3% | 40.6% | 13.7% | 14.2% | 18.4% | 42.7% | 26.7% | 16.4% |
| EPS (Basic) | $1.90 | $3.57 | $1.18 | $1.13 | $1.44 | $3.23 | $1.96 | $1.28 |
| EPS (Diluted) | $1.87 | $3.52 | $1.17 | $1.11 | $1.42 | $3.19 | $1.94 | $1.27 |
| Shares Outstanding (Basic) | 5.87B | 5.97B | 6.09B | 6.18B | 6.35B | 6.81B | 7.44B | 7.82B |
| Shares Outstanding (Diluted) | 5.98B | 6.06B | 6.16B | 6.26B | 6.42B | 6.90B | 7.51B | 7.87B |
| Dividends Per Share | $1.38 | $1.30 | $1.22 | $1.12 | $1.04 | $0.96 | $0.88 | $0.80 |